CHRS (Coherus BioSciences) GF Score : 45/100 (As of Apr. 08, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences GF Score?

Coherus BioSciences has the GF Score of 45, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 2/10
2. Profitability Rank : 2/10
3. Growth Rank : 1/10
4. GF Value Rank : 2/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Coherus BioSciences might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Coherus BioSciences's GF Score

For the Biotechnology subindustry, Coherus BioSciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's GF Score distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's GF Score falls into.

Save Embed

;

Save Embed

;

Coherus BioSciences (NAS:CHRS) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Coherus BioSciences GF Score Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

8C5:Germany

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Executives

Dennis M Lanfear	director, officer: President and CEO	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell	officer: Chief Financial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael	officer: See Remarks	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider	officer: Chief Commercial Officer	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey	director	C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton	director	46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler	officer: Chief Scientific Officer	333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti	officer: Chief, Quality & Compliance	COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret	officer: Chief Financial Officer	ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper	director	150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson	director	ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas	director	1170 FAIRFAX STREET, BIRMINGHAM MI 48009